Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Acute Care I > ACS: STEMI > Flashcards

ACS: STEMI Flashcards

1
Q

Requirements for STEMI on ECG

A

> /= 2 contiguous leads w/ ST-segment elevation >/= 2.5mm in men < 40 years
/= 2 mm in men >/= 40 years
/= 1.5mm in women in leads V2-V3 &/or >/= 1mm in other leads (in absence of LVH or LBBB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

STEMI occurs due to what?
Exposure of circulating blood to cholesterol-rich material w/n plaque stimulates what? which has what effect?

A

erosion or sudden rupture of atherosclerotic plaque w/n wall of coronary artery
blood clotting (thrombosis); obstructs blood flow w/n the coronary artery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

STEMI is most often caused by what?
As soon as blood supply is interrupted what occurs?
In animal models of experimental coronary artery occlusion, a ‘wave-front’ of what goes where?
In those who survive STEMI, infarcted muscle is gradually replaced by what? & extent of damage will determine what? & is a determinant of what?

A

complete & persistent occlusion of a coronary artery thrombus.
myocardial damage begins & the longer the blood supply is occluded, the greater the amount of heart muscle lost.
myocardial injury spreads from inner layer of heart muscle (subendocardial myocardium) to outermost layer (sub-epicardial myocardium), whereupon the infarction is then said to be ‘full thickness’.
fibrosis; contractility; heart failure & longer-term survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

NSTEMI may be a flow-limiting condition such as?

A

stable plaque
vasospasm-Prinzmetal angina
coronary embolism
coronary arteritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Non-coronary injury to heart can also produce NSTEMI, these injuries can include?

A

cardiac contusion
myocarditis
presence of cardiotoxic substances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Conditions unrelated to coronary arteries or myocardium itself can lead to NSTEMI because increased O2 demand cannot be met. These conditions include?

A

Hypotension
HTN
Tachycardia
AS
PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

STEMI patient who is a candidate for reperfusion.
Initially seen at PCI-capable hospital, what are the following steps?

A

Send to cath lab for primary PCI; FMC-deve time </= 90 min
Diagnostic angiogram
1 of the following 3:
Medical therapy only
PCI
CABG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

STEMI patient who is a candidate for reperfusion
Initially seen at a non-PCI capable hospital, what decision is initially made?

A

Patient is either transferred for primary PCI; DIDO </=30 min; FMC-device time ASAP and </= 120 min

or

Administer fibrinolytic agent w/n 30 min of arrival when anticipated FMC-device time > 120 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

STEMI patient who is a candidate for reperfusion
For patients who receive fibrinolytic agent, what is the next step?

A

Urgent transfer for PCI for patients w/ evidence of failed reperfusion or reocclusion

or

Transfer for angiography and revascularization w/n 3-24 hrs for other patients as part of an invasive strategy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Primary PCI & STEMI should be done when:
Ischemic symptoms are < how long?
Ischemic symptoms are < how long and contraindications to what?
the patient experiences what irrespective of time delay from MI onset?

A

12 hours
12 hours and contraindications to fibrinolytic therapy irrespective of time delay from FMC
Cardiogenic shock or acute severe HF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Placement of what is useful in primary PCI for patients w/ STEMI?

A

bare-metal stent or drug-eluting stent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bare Metal Stent (BMS) should be used in patients w/?

A

high bleeding risk
inability to comply w/ 1 yr of DAPT
anticipated invasive or surgical procedures in the next yr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drug-eluting stent (DES) should not be used in primary PCI for patients w/ STEMI who are what?

A

unable to tolerate or comply w/ a prolonged course of DAPT because of the increased risk of stent thrombosis w/ premature discontinuation of one or both agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Anti-Platelet therapy to use for STEMI patients

A

Aspirin
P2Y12 inhibitors
IV GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin in selected patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aspirin
Loading dose before PCI?
daily maintenance dose? Preferred maintenance dose?

A

162-325mg
81-325mg daily
81mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

P2Y12 inhibitors
Loading doses

A

Clopidogrel 600 mg as early as possible or at time of PCI
Prasugrel 60 mg as early as possible or at time of PCI
Ticagrelor 180 mg as early as possible or at time of PCI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

P2Y12 inhibitors
Maintenance doses and duration of therapy
DES placed: Continue therapy for?

A

1 year
clopidogrel 75mg daily
prasugrel 10mg daily
ticagrelor 90 mg twice a day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

P2Y12 inhibitors
Maintenance doses and duration of therapy
BMS placed: continue therapy for?

A

1 year
Clopidogrel 75mg daily
prasugrel 10mg daily
ticagrelor 90mg twice a day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

P2Y12 inhibitors
Maintenance doses and duration of therapy
DES placed what medications are continued beyond 1 year?
Patients w/ STEMI or prior stroke or TIA should receive?

A

clopidogrel, prasugrel, ticagrelor
prasugrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

IV GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin in selected patients
What medications are used here?

A

Abciximab
Tirofiban
Eptifibatide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IV GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin in selected patients
Abciximab loading dose? maintenance?
Tirofiban loading dose? maintenance?
Eptifibatide loading dose? maintenance? what is administered 10 min after loading dose?

A

0.25mg/kg IV bolus then 0.125mcg/kg/min (max 10mcg/min)
25mcg/kg IV bolus then 0.15 mcg/kg/min
180mcg/kg IV bolus then 2mcg/kg/min followed by a second 180mcg/kg bolus 10 min after initial loading dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

IV GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin in selected patients
Tirofiban dose reduction for CrCl < 30ml/min?
Eptifibatide dose reduction for CrCl < 50 ml/min? avoid giving this in patients on?

A

reduce infusion by 50%
reduce infusion by 50%; Hemodialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Anticoagulation therapy
UFH
With GP IIb/IIIa receptor antagonist planned what dose is administered to achieve therapeutic what?
W/o GP IIb/IIIa receptor antagonist planned what does is administered to achieve therapuetic what?

A

50-70 U/kg IV bolus to achieve therapuetic ACT
70-100 U/kg IV bolus to achieve therapuetic ACT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Anticoagulation therapy
Bivalirudin
what dose is given w/ or w/o prior treatment w/ UFH?
If needed an additional bolus of what can be given?

A

0.75mcg/kg IV bolus then 1.75 mcg/kg/hr infusion
0.3 mg/kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Anticoagulation therapy
Bivalirudin
Reduce infusion to what w/ estimated CrCl < 30ml/min?
Preferred over UFH w/ GP IIb/IIIa receptor antagonist in patients w/ what?

A

1mg/kg/hr
high risk of bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Anticoagulation therapy
What medication is not recommended as sole anticoagulant for primary PCI?

A

Fondaparinux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Recommendations for Reperfusion at a Non-PCI hospital:
Ischemic symptoms < how long?
Evidence of ongoing ischemia between how long after onset, and a large are of what, or the patient is experiencing what?

A

12 hours
12-24hours; myocardium at risk; hemodynamic instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Recommendations for Reperfusion at a Non-PCI hospital:
Not recomended if ST depression except if?
or when associated w/ ST-elevation in lead?

A

true posterior (inferobasal) MI suspected
aVR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Doses of fibrinolytic therapy:
Streptokinase?

A

1.5 million units over 30-60 min IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Doses of fibrinolytic therapy:
Alteplase (tPA)?

A

15mg IV bolus
0.75mg/kg IV over 30m min (up to 50 mg)
then 0.5mg/kg IV over 60 min (up to 35mg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Doses of fibrinolytic therapy:
Tenectaplase
if < 60kg
if 60 to <70kg
if 70 to <80kg
if 80 to <90kg
if >/= 90kg
it is recommended to reduce dose to what in what patients?

A

30mg
35mg
40mg
45mg
50mg
half dose in patients >/= 75 years old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Doses of antiplatelet co-therapies w/ fibrinolytic therapy
Aspirin?

A

Starting dose of 150-300mg PO (or 75-250mg IV if PO is not possible), followed by maintenance dose of 75-100mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Doses of antiplatelet co-therapies w/ fibrinolytic therapy
Clopidogrel loading dose then maintenance dose?
In patients >/= 75 years of age loading dose then maintenance dose?

A

Loading dose of 300mg PO followed by maintenance dose of 75mg/day.
75 mg followed by maintenance dose of 75mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Doses of anticoagulant co-therapies w/ fibrinolytic therapy
Enoxaparin
In patients < 75 years of age

A

30 mg IV bolus followed 15 min later by 1mg/kg s.c. q12 hrs until revascularization or hospital dc for a max of 8 days.
the first 2 doses of s.c. should not exceed 100mg per injection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Doses of anticoagulant co-therapies w/ fibrinolytic therapy
Enoxaparin
In patients >/= 75 years of age

A

no IV bolus; start w/ first s.c. dose of 0.75mg/kg w/ max of 75mg per injection for the first two s.c. doses

36
Q

Doses of anticoagulant co-therapies w/ fibrinolytic therapy
Enoxaparin
In patients w/ eGFR < 30ml/min/1.73cm2 regardless of age the s.c. doses are given at what frequency?

A

q 24 hrs

37
Q

Doses of anticoagulant co-therapies w/ fibrinolytic therapy
UFH
Loading dose and maintenance?
Target aPTT?

A

60 IU/kg IV bolus w/ a max of 4000 IU follwed by IV infusion of 12 IU/kg w/ a max of 1000 IU/hour for 24-48 hours.

50-70s or 1.5-2.0 times that of control to be monitored at 3, 6, 12, and 24 hrs.

38
Q

Doses of anticoagulant co-therapies w/ fibrinolytic therapy
Fondaparinux
Only given with what other medication?
loading dose then maintenance for how long?

A

Streptokinase
2.5mg IV bolus followed by a s.c. dose of 2.5mg daily up to 8 days or hospital dc

39
Q

Indications for Transfer for Angio after fibrinolysis

A

Cardiogenic Shock or acute severe HF that develops after initial presentation
Intermediate- or high-risk findings predischarge noninvasive ischemia testing
Spontaneous or easily provoked myocardial ischemia
Failed reperfusion or reocclusion after fibrinolytic therapy
Stable patients after successful fibrinolysis before dc and ideally between 3 and 24 hrs

40
Q

Absolute Contraindications for Fibrinolytic therapy

A

Any prior ICH
Known structural cerebral vascular lesion (eg, AVM)
Known malignant intracranial neoplasm (primary or metastatic)
Ischemic stroke w/n 3mo (except acute ischemic stroke w/n 4.5 hrs)
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Significant closed-head or facial trauma w/n 3 mo
Intracranial or intraspinal surgery w/n 2 mon
Severe uncontrolled hypertension (unresponsive to emergency therapy)
For streptokinase prior treatment w/n the previous 6 mo

41
Q

Relative Contraindications for Fibrinolytic therapy

A

Hx of chronic, severe, poorly controlled HTN
Significant HTN on presentation SBP > 180 or DBP > 110)
Hx of prior ischemic stroke > 3 mo
Dementia
Known intracranial pathology not covered in absolute contraindications
Traumatic or prolonged (> 10min) CPR
Major surgery < 3wk
Recent (w/ 2-4wk) internal bleeding
Noncompressible vascular punctures
Pregnancy
Active peptic ulcer
PO anticoagulant therapy

42
Q

Routine Medical Therapies: Beta-Receptor Antagonists
Indications

A

PO: All patients w/o contraindication; IV Patients with refractory HTN or ongoing ischemia w/o contraindication

43
Q

Routine Medical Therapies: Beta-Receptor Antagonists
Dose/admin
Metoprolol Tartrate
Carvedilol
IV Metoprolol Tartrate

A

Metoprolol tartrate 25-50mg q6-12hr PO then transition over next 2-3days to BID dosing of metoprolol tartrate or to daily metoprolol succinate, titrate to daily dose of 200 mg as tolerated
Carvedilol 6.25mg BID , titrate to 25mg BID as tolerated
Metoprolol Tartrate IV 5mg q5min as tolerated up to 3 doses, titrate to HR and BP

44
Q

Routine Medical Therapies: Beta-Receptor Antagonists
Avoid/Caution

A

Signs of HF
Low output state
Increased risk of cardiogenic shock
Prolonged First-degree or high-grade AV block
Reactive Airway disease

45
Q

Routine Medical Therapies: ACE Inhibitors
Indications

A

For patients with anterior infarction
post-MI LV systolic dysfunction (EF</= 40%) or HF
May be given routinely to all patients w/o contraindications

46
Q

Routine Medical Therapies: ACE Inhibitors
Dose/Admin
Lisinopril
Captopril
Ramipril
Trandolapril

A

2.5-5mg/d to start; titrate to 10mg/d or higher as tolerated
6.25-12.5 mg TID to start; titrate to 25-30mg TID as tolerated
2.5mg BID to start; titrate to 5mg BID as tolerated
test dose 0.5mg; titrate up to 4mg daily as tolerated

47
Q

Routine Medical Therapies: ACE Inhibitors
Avoid/Caution

A

Hypotension
Renal failure
Hyperkalemia

48
Q

Routine Medical Therapies: ARB
Indicaitons

A

For patients intolerant of ACE inhibitors

49
Q

Routine Medical Therapies: ARB
Dose/Admin
Valsartan

A

20mg BID to start; titrate up to 160mg BID as tolerated

50
Q

Routine Medical Therapies: ARB
Avoid/Caution

A

Hypotension
Renal failure
Hyperkalemia

51
Q

Routine Medical Therapies: Statins
Indications

A

All patients w/o contraindications

52
Q

Routine Medical Therapies: Statins
Dose/Admin

A

High dose atorvastatin 80mg daily

53
Q

Routine Medical Therapies: Statins
Avoid/Caution

A

Caution w/ drugs metabolized via CYP3A4 fibrates
Monitor for myopathy, hepatic toxicity
Combine w/ diet and lifestyle therapies
Adjust dose as dictated by targets for LDL cholesterol and non-HDL cholesterol reduction

54
Q

Routine Medical Therapies: Nitroglycerin
Indications

A

Ongoing chest pain
Hypertension and HF

55
Q

Routine Medical Therapies: Nitroglycerin
Dose/Admin

A

0.4mg sublingual q5min up to 3 doses as BP allows
IV dosing to begin at 10 mcg/min; titrate to desired BP effect

56
Q

Routine Medical Therapies: Nitroglycerin
Avoid/Caution

A

Avoid in suspected RV infarction
Avoid w/ SBP < 90 or if SBP >30mg below baseline
Avoid if recent (24-48 hr) use of 5-Phosphodiesterase inhibitors

57
Q

Routine Medical Therapies: O2
Indications

A

Clinically significant Hypoxemia (SpO2 < 90%)
HF
Dyspnea

58
Q

Routine Medical Therapies: O2
Dose/Admin

A

2-4 L/min via NC
Increase rate or change to face mask as needed

59
Q

Routine Medical Therapies: O2
Avoid/Caution

A

COPD and CO2 retention

60
Q

Routine Medical Therapies: Morphine
Indication

A

Pain
Anxiety
Pulmonary edema

61
Q

Routine Medical Therapies: Morphine
Dose/Admin

A

4-8mg IV initially w/ lower doses in elderly
2-8mg q5-15min if needed

62
Q

Routine Medical Therapies: Morphine
Avoid/Caution

A

Lethargic or moribund patient
Hypotension
Bradycardia
Known hypersensitivity

63
Q

Class I Recs
Measurement of LVF
One of the strongest predictors of what?
Most commonly evaluated w/ what?
If significatn LV systolic dysfunction during initial hospitalization, LVF should be reevaluated when?

A

survival in patients w/ STEMI
contrast ventriculography during cardiac cath or TEE day 2-3
>/=40 days later to assess need for ICD therapy after allowance for recovery from myocardial stunning

64
Q

Class I Recs
Type of rehab?
Education needed?

A

Cardiac rehab
med adherence, appointments, diet, exercise, smoking cessation

65
Q

Complications of STEMI
Cardiogenic Shock
Definition:

A

Persistent Hypotension (SBP <90) despite adequate filling status w/ signs of hyoperfusion &/or if inotropes &/or mechanical support are needed to maintain SBP > 90

66
Q

Complications of STEMI
Cardiogenic Shock
Causes

A

LV infarction or mechanical comps (papillary muscle rupture, vent septal rupture, free-wall rupture w/ tamponade, RV infarctions)

67
Q

Complications of STEMI
Cardiogenic Shock
Occurs in what % of all STEMI cases & remains to be what?

A

6-10%; leading cause of death w/ in hospital mortality rates 50%

68
Q

Complications of STEMI
Cardiogenic Shock
ID mechanism and correct any reversible causes such as?

A

hypovolemia
drug-induced hypotension
arrhythmias
tamponade

69
Q

Complications of STEMI
Heart Failure
Treatment includes?

A

diuretics
vasodilators
inotropic agents when required
RAAS inhibitors as tol.
Beta blockers as tol.

70
Q

Complications of STEMI
RV infarction
Occurs in ~ how many patients w/ what?
Associated w/?
Symptoms?

A

1/3 of patients w/ inferior STEMI d/t proximal occlusion of RCA
higher mortality risk
Hypotension, clear lung fields
elevated JVP are characteristic

71
Q

Complications of STEMI
RV infarction
ECG shows?
Treatment?

A

1mm STEE in lead V1 & in R precordial lead V4R are most sensitive markers of RV injury
Maintenance of RV preload, reduction of RV afterload, restore NSR, Inotropic support, prn & immediate reperfusion if not already performed.

72
Q

Complications of STEMI
RV infarction
AVOID what?

A

Nitrates and diuretics

73
Q

Complications of STEMI
Mitral Regurgitation
Due to what?
S/Sx are?

A

Papillary muscle rupture or post-infarction LV remodeling w/ displacement of the papillary muscles, leaflet tethering, and annular dilatation

pulmonary edema & or Shock

74
Q

Complications of STEMI
Mitral Regurgitation
Consider what while temporary stabilization is attempted w/ what?
Treatment?

A

urgent surgery; medical therapy & IABP
timely reperfusion, diuretics, afterload reduction

75
Q

Complications of STEMI
Ventricle septal rupture
Usually c/w what?
what is necessary?

A

loud systolic murmur, HF, Shock
Emergency surgical repair

76
Q

Complications of STEMI
Free-wall rupture
S/Sx?

A

Recurrent chest pain
ST-T wave changes rapid progression to HD collapse
Electromechanical dissociation
Death

77
Q

Complications of STEMI
Free-wall rupture
Usually seen w/?
PSA w/ contained rupture & tamponade can be seen on what?
Consider what? Mortality rates as high as?

A

first MI, ant infarction, elderly, women
TTE
Emergency surgery; 60%

78
Q

Complications of STEMI
Ventricular Arrhythmias
Due to what?
ICD is indicated before DC wwhen?

A

ongoing ischemia, HD & electrolyte abnormalities, reentry, enhanced automaticity
if sustained VT/VF > 48 hours after STEMI

79
Q

Complications of STEMI
AF/SVT
Due to what?

A

excessive sympathetic stim
atrial stretch d/t LV or RV volume/pressure overload
Atrial infarction
pericarditis
electrolyte abnormalities
hypoxia
underlying lung disease

80
Q

Complications of STEMI
Bradyarrhythmias
SB is common early after STEMI, Particularly with what location? d/t what?
Hold what?
Consider what for treatment?

A

inferior location d/t increased vagal tone
beta blockers
+/- atropine, temp pacing

81
Q

Complications of STEMI
Bradyarrhythmias
AV block/BBB is associated w/ what?
AV block of varying degree and persistnet BBB develop in ~ what % of patients?
High-grade AV block & persistent BBB assoc. w/ what?

A

extent of infarction
5-7%
worse short- & long term prognosisT

82
Q

Complications of STEMI
Bradyarrhythmias
Temp pacing is indicated for what?

A

symptomatic bradyarrhythmias unresponsive to medical treatment

83
Q

Complications of STEMI
Pericarditis
Treatment?

A

ASA

84
Q

Complications of STEMI
Thromboembolism
Prevention and treatment are similar to what?

A

other critically ill patients

85
Q

Complications of STEMI
Bleeding
General rec is to transfuse when Hgb < what?

A

8mg/dL

86
Q

Complications of STEMI
Renal complication?
Hyperglycemia: goal BG is what? Avoid what?

A

AKI
< 180mg/dL; hypoglycemia

Acute Care I (24 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions